Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
550 participants
OBSERVATIONAL
2021-06-23
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genotyping of Non-small Cell Lung Cancer
NCT02002117
Established Lung Cancer Cell Line and Stroma Cell From Surgical Tissue
NCT01058811
Formatting the Risk Prediction Models for Never-Smoking Lung Cancer
NCT05572944
Gene Mutations in Non-Small Cell Lung Cancer Cells
NCT00977509
Respiratory Muscle Performance and Functional Capacity in Primary Stage IIIb and IV Lung Cancer
NCT01078883
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. To enroll 550 patients who fit the criteria of this study in the enrolled period.
2. To perform large-scale NGS analysis for specific populations, to create a map containing important genetic characteristics to help understand the mechanisms of drug resistance, and to find novel treatment strategies.
3. To collect tumor sample for NGS testing
4. To record previous therapeutic agents and accompanying treatment response and adverse events
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Pathological reports showed adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous carcinoma, and sacromatoid carcinoma.
3. For patients with squamous cell carcinoma, only never smokers and light smokers (less than 10 cigarettes per day) are indicated.
4. For patients with advanced EGFR (-) and ALK (-) adenocarcinoma or other histological types regardless of EGFR/ALK status, treatment-naïve or failure to ≤ two lines of systemic treatment is allowed.
5. For patients with advanced EGFR (+) or ALK (+) adenocarcinoma, failure to ≤ two lines of systemic treatment, including tyrosine kinase inhibitor is allowed.
6. For patients with advanced EGFR exon 20 insertion/mutation (excluding T790M mutation) adenocarcinoma, failure to ≤ four lines of systemic treatment, including tyrosine kinase inhibitor is allowed.
7. Reacquisition of tumor tissue after the failure of previous systemic treatment
8. Willingness to provide the residual biopsy/operative slides.
9. Life expectancy more than 3 months.
10. Patients fully understand the protocol with the willingness to have regular follow-up.
Exclusion Criteria
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Health Research Institutes, Taiwan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nai-Jung Chiang
Role: PRINCIPAL_INVESTIGATOR
National Health Research Institutes, Taiwan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chang Gung Medical Foundation
Chiayi City, , Taiwan
Dalin Tzu Chi Hospital
Dalin, , Taiwan
Chang Gung Medical Foundation
Kaohsiung City, , Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
Chung Shan Medical University Hospital
Taichung, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
National Cheng Kung University Hospital
Tainan City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Medical University-Shuang Ho Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Tri-Service General Hospital
Taipei, , Taiwan
Taoyuan General Hospital
Taoyuan District, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yu-Ching Lin, MD
Role: primary
Chun-Liang Lai
Role: primary
Chin-Chou Wang, PhD
Role: primary
Chong, PhD
Role: primary
Te-Chun Hsia, MD
Role: primary
Gee-Chen Chang, PhD
Role: primary
Tsung-Ying Yang, PhD
Role: primary
Wu-Chou Su, PhD
Role: primary
Chih-Hsin Yang, PhD
Role: primary
Kang-Yun Lee, MD
Role: primary
Yung-Hung Luo, PhD
Role: primary
Chih-Hsin U Yang
Role: primary
Shih-Wei Lee, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T1521
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.